IDXX
IDEXX Laboratories, Inc.
Healthcare · Diagnostics & Research · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The model score of 56.6 reflects a company that excels in profitability (18.4) and demonstrates adequate growth and momentum (15.0 each), but is meaningfully dragged down by a financial health sub-score of 12.0 and zero scores in dividend and theme, which together account for a large portion of the available scoring headroom.
- The confidence level of 8.0 out of 10 is relatively high, based on 8 of 10 core metrics being successfully mapped from the SEC EDGAR 10-K filing, meaning the score is well-grounded in actual reported data rather than estimated inputs.
- The best-fit goal profile alignment of 68.5 for aggressive growth — compared to the weakest fit of 49.2 for dividend income — explains why the overall composite score sits at a moderate 56.6; the model is rewarding the growth and profitability axes while penalizing the absence of income characteristics and macro theme exposure.
Why Not Higher
- The financial health sub-score of 12.0 is the most significant constraint on a higher overall score, as elevated leverage and the associated interest coverage metrics reduce the model's assessment of balance sheet safety and limit the financial health contribution to the composite.
- Zero scores in both the dividend (0.0) and theme (0.0) sub-categories eliminate 40 points of maximum possible scoring from the composite, and without any dividend program or identifiable macro thematic exposure in the filing, these categories cannot contribute positively regardless of how strong the other metrics are.
Data Confidence
8 / 10
High — most data fields present
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
IDEXX Laboratories, Inc. is a U.S.-based diagnostics and research company operating primarily in veterinary diagnostics, software, and water and livestock testing. The company is best known for its companion animal diagnostics segment, supplying veterinary practices with analyzers, rapid assay tests, and cloud-based practice management software. IDEXX occupies a dominant position in the veterinary diagnostics market, supported by recurring consumable revenue from its installed instrument base. The model assigned IDEXX a score of 56.6/100, reflecting a company with genuinely strong underlying business fundamentals that are partially offset by balance sheet and structural concerns visible in the FY2025 10-K filing. The profitability sub-score of 18.4 out of 20 is a standout, indicating robust net margins, operating margins, and return on assets — a hallmark of IDEXX's high-value recurring diagnostics model. Growth scored 15.0 and momentum also scored 15.0, signaling consistent but not accelerating top- and bottom-line performance across recent quarters. Financial health, however, scored only 12.0, pointing to meaningful leverage on the balance sheet and a balance sheet structure that warrants monitoring. The dividend sub-score of 0.0 confirms IDEXX does not distribute earnings to shareholders via dividends, and the theme score of 0.0 indicates no macro thematic tailwinds were mapped from the filing. The core research tradeoff for IDEXX is between a highly profitable, recurring-revenue business model with durable competitive positioning in veterinary diagnostics and a leveraged balance sheet combined with limited near-term catalysts beyond organic growth. The research label of 'Research Further' and the aggressive growth goal profile alignment at 68.5 suggest this is a candidate best suited for researchers focused on quality compounders in healthcare services, who are willing to weigh balance sheet risk against consistent profitability metrics.
Plain English
IDEXX Laboratories makes the diagnostic equipment and tests that veterinarians use to check your pet's health — think blood analyzers, urine tests, and the software that runs a vet clinic. The model score of 56.6 out of 100 reflects a company that is very profitable and growing steadily, but carries notable debt and scores zero on dividends and macro themes, which pulls the overall score into the mid-range. The Medium risk rating means there are real financial health concerns, particularly around leverage, that a researcher should investigate before forming a view. This is not a low-risk, income-focused research candidate — it fits best for those studying aggressive growth opportunities in healthcare diagnostics.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 18.4 out of 20 — the highest individual sub-score in the model — reflects IDEXX's ability to generate strong net and operating margins from its recurring consumable and software revenue streams, which are structurally linked to its large installed base of diagnostic instruments.
- Both the growth sub-score (15.0) and momentum sub-score (15.0) indicate consistent year-over-year revenue, net income, and EPS expansion alongside quarterly improvement in financials, suggesting the business is not experiencing top-line deceleration as captured in the FY2025 10-K filing.
- The aggressive growth goal profile alignment score of 68.5 — the best-fit profile for this company — suggests the model views IDEXX's combination of revenue growth, margin strength, and earnings momentum as characteristic of a durable compounder within the diagnostics and research sector.
Bear Case
- The financial health sub-score of 12.0 out of 20 indicates elevated leverage and less robust interest coverage relative to best-in-class peers, which raises questions about balance sheet resilience if revenue growth were to slow or credit conditions were to tighten.
- The dividend sub-score of 0.0 confirms there is no dividend program, meaning researchers focused on income generation or capital return discipline will find no filing-based evidence of shareholder distributions from free cash flow.
- The theme sub-score of 0.0 signals that the FY2025 10-K filing did not map to any of the macro thematic categories tracked by the model, which may indicate IDEXX's growth narrative is largely self-contained and dependent on the veterinary diagnostics market cycle rather than broader secular tailwinds.
What Could Change the Picture
Bullish Triggers
- Evidence in a future 10-K filing of meaningful debt reduction or improved interest coverage ratios would raise the financial health sub-score and could push the overall model score meaningfully above 60, strengthening the research case.
- Acceleration in revenue growth rates or a notable expansion in net or operating margins in subsequent quarterly filings would improve both the growth and momentum sub-scores, which are currently solid but not at maximum levels, further validating the aggressive growth research thesis.
Bearish Triggers
- A deterioration in the financial health sub-score in future filings — driven by further leverage increases, a weakening interest coverage ratio, or balance sheet contraction — would increase the risk profile and could shift the risk rating toward High.
- A deceleration in the momentum sub-score, reflected in declining quarterly revenue or margin improvement trends in future 10-K or interim filings, would undermine the consistency narrative that currently supports IDEXX's mid-range score and aggressive growth profile alignment.
Red Flags
- The financial health sub-score of 12.0 flags leverage as a meaningful concern, and researchers should examine the specific debt-to-equity and interest coverage figures in the FY2025 10-K to assess whether the capital structure introduces refinancing or solvency risk under adverse conditions.
Risk Profile
Medium RiskThe Medium risk rating for IDEXX reflects a tension between its high-quality, recurring-revenue profitability profile and the elevated leverage visible in the financial health sub-score of 12.0 from the FY2025 10-K filing — the company is not a low-risk defensive holding, but neither does the filing data indicate acute financial distress. Researchers should be aware that the balance sheet structure introduces sensitivity to interest rate and credit conditions that is not offset by a dividend or capital return program.
Key Catalysts to Watch
The key filing-derived factors to monitor for IDEXX are trends in the financial health metrics — particularly leverage ratios and interest coverage — across future annual filings, as improvement here represents the clearest path to a higher model score. Sustained momentum in quarterly revenue and margin improvement, as captured in the momentum sub-score, will also be critical to watch as a signal of whether the business continues to compound at a pace consistent with its aggressive growth profile alignment.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.